Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Inflammation-based scores, such as the neutrophil-to-lymphocyte ratio (NLR), have been associated with prognosis in hepatocellular carcinoma (HCC); but variable cut-off values and potential lack of specificity have limited the utility of NLR. This study evaluates NLR in a large cohort of HCC patients. Methods: We retrospectively reviewed 789 HCC cases (1993–2017) for demographics, tumor characteristics, treatment, and survival. NLR was stratified into NLR ≥1.5 and NLR ≥3 and analyzed for correlation with American Joint Committee on Cancer (AJCC) and Barcelona Clinic Liver Cancer (BCLC) stages. In 235 patients who underwent liver resection, survival and recurrence were evaluated by NLR. Results: In 789 HCC cases, mean NLR was increased with advanced AJCC and BCLC stages. Hepatitis C patients were less likely to have NLR ≥1.5 and ≥3. Non-alcoholic steatohepatitis patients were more likely to have NLR ≥3. Patients with tumor size >5 cm, rupture, or macrovascular invasion were more likely to have NLR ≥3. In patients treated with resection, NLR ≥3 predicted early recurrence (odds ratio [OR] 4.14, P<0.01) and overall recurrence (OR 4.05, P<0.01). Mean NLR was 4.30 in those with recurrence and 2.75 in those without recurrence. Patients with NLR ≥3 showed significantly worse survival compared to those with NLR <3 (P<0.01 by log-rank test). Conclusions: Elevated NLR is associated with advanced cancer stage and aggressive tumor characteristics, such as large size, rupture, and invasion. NLR ≥3 was associated with early and overall recurrence after resection but varied with etiology. NLR may be a useful biomarker in predicting recurrence for HCC patients undergoing curative resection, but further studies are required to elucidate the effect of disease etiology.
Abstract
Background/Aims: Inflammation-based scores, such as the neutrophil-to-lymphocyte ratio (NLR), have been associated with prognosis in hepatocellular carcinoma (HCC); but variable cut-off values and potential lack of specificity have limited the utility of NLR. This study evaluates NLR in a large cohort of HCC patients. Methods: We retrospectively reviewed 789 HCC cases (1993–2017) for demographics, tumor characteristics, treatment, and survival. NLR was stratified into NLR ≥1.5 and NLR ≥3 and analyzed for correlation with American Joint Committee on Cancer (AJCC) and Barcelona Clinic Liver Cancer (BCLC) stages. In 235 patients who underwent liver resection, survival and recurrence were evaluated by NLR. Results: In 789 HCC cases, mean NLR was increased with advanced AJCC and BCLC stages. Hepatitis C patients were less likely to have NLR ≥1.5 and ≥3. Non-alcoholic steatohepatitis patients were more likely to have NLR ≥3. Patients with tumor size >5 cm, rupture, or macrovascular invasion were more likely to have NLR ≥3. In patients treated with resection, NLR ≥3 predicted early recurrence (odds ratio [OR] 4.14, P<0.01) and overall recurrence (OR 4.05, P<0.01). Mean NLR was 4.30 in those with recurrence and 2.75 in those without recurrence. Patients with NLR ≥3 showed significantly worse survival compared to those with NLR <3 (P<0.01 by log-rank test). Conclusions: Elevated NLR is associated with advanced cancer stage and aggressive tumor characteristics, such as large size, rupture, and invasion. NLR ≥3 was associated with early and overall recurrence after resection but varied with etiology. NLR may be a useful biomarker in predicting recurrence for HCC patients undergoing curative resection, but further studies are required to elucidate the effect of disease etiology.
참고문헌 (49)
- "World cancer Report 2014"[URL]
- Choo SP, "Comparison of hepatocellular carcinoma in Eastern versus Western populations", Cancer, 122, pp.3430~3436 (2016)
- El-Serag HB, "Hepatocellular carcinoma", N Engl J Med, 365, pp.1118~1127 (2011)
- Petrick JL, "Future of hepatocellular carcinoma incidence in the United States forecast through 2030", J Clin Oncol, 34, pp.1787~1794 (2016)
- El-Serag HB, "Epidemiology of hepatocellular carcinoma in the United States : where are we? Where do we go", Hepatology, 60, pp.1767~1775 (2014)
- Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
- European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Pompili M, "Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3 cm. Results of a multicenter Italian survey", J Hepatol, 59, pp.89~97 (2013)
- Tralhão JG, "Treatment of tumour recurrence after resection of hepatocellular carcinoma. Analysis of 97 consecutive patients", Eur J Surg Oncol, 33, pp.746~751 (2007)
- Shimada K, "A long-term followup and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy", Cancer, 104, pp.1939~1947 (2005)
- Mazzaferro V, "Milan criteria in liver transplantation for hepatocellular carcinoma:an evidence-based analysis of 15 years of experience", Liver Transpl, 17(Suppl 2), pp.S44~S57 (2011)
- Roayaie S, "Recurrence of hepatocellular carcinoma after liver transplant : patterns and prognosis", Liver Transpl, 10, pp.534~540 (2004)
- Onaca N, "Expanded criteria for liver transplantation in patients with hepatocellular carcinoma : a report from the International Registry of Hepatic Tumors in Liver Transplantation", Liver Transpl, 13, pp.391~399 (2007)
- Vibert E, "Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients : a critical factor", Am J Transplant, 10, pp.127~137 (2010)
- Vora SR, "Serum alphafetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma", Oncologist, 14, pp.717~725 (2009)
- Coussens LM, "Inflammation and cancer", Nature, 420, pp.860~867 (2002)
- Chew V, "Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients", J Hepatol, 52, pp.370~379 (2010)
- Gao Q, "Intratumoural balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection", J Clin Oncol, 25, pp.2586~2593 (2007)
- Wada Y, "Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration", Hepatology, 27, pp.407~414 (1998)
- Qin LX, "Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma", Cancer Microenviron, 5, pp.203~209 (2012)
- Najjar M, "Pretreatment neutrophil-lymphocyte ratio : useful prognostic biomarker in hepatocellular carcinoma", J Hepatocell Carcinoma, 5, pp.17~28 (2018)
- Cao Y, "Prediction of longterm survival rates in patients undergoing curative resection for solitary hepatocellular carcinoma", Oncol Lett, 15, pp.2574~2582 (2018)
- Chan AW, "Prognostic Nutritional Index(PNI)predicts tumor recurrence of very early", early stage hepatocellular carcinoma after surgical resection, 2015, pp.22, 4138~4148
- Fu SJ, "Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy", Med Oncol, 30, pp.721~ (2013)
- Hung HC, "Impact of neutrophil to lymphocyte ratio on survival for hepatocellular carcinoma after curative resection", J Hepatobiliary Pancreat Sci, 24, pp.559~569 (2017)
- Pang S, "The predictive value of integrated inflammation scores in the survival of patients with resected hepatocellular carcinoma : a retrospective cohort study", Int J Surg, 42, pp.170~177 (2017)
- Ren Z, "Survival prediction model for postoperative hepatocellular carcinoma patients", Medicine (Baltimore), 96, pp.e7902~ (2017)
- Shimoda M, "Risk factors for early recurrence of single lesion hepatocellular carcinoma after curative resection", World J Surg, 40, pp.2466~2471 (2016)
- Yang HJ, "Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma : a propensity score-based analysis", World J Gastroenterol, 22, pp.5088~5095 (2016)
- Yu Y, "Preoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict microvascular invasion in patients with hepatocellular carcinoma", Oncotarget, 8, pp.79722~79730 (2017)
- Zheng J, "Utility of serum inflammatory markers for predicting microvascular invasion and survival for patients with hepatocellular carcinoma", Ann Surg Oncol, 24, pp.3706~3714 (2017)
- Wang Y, "The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy : a systemic review and meta-analysis", Int J Surg, 55, pp.73~80 (2018)
- Huang GQ, "Stratified neutrophil-to-lymphocyte ratio accurately predict mortality risk in hepatocellular carcinoma patients following curative liver resection", Oncotarget, 7, pp.5429~5439 (2016)
- Guo, ZX, "Correlation of preoperative neutrophil-to-lymphocyte ratio to prognosis of young patients with hepatocellular carcinoma", Ai Zheng, 28, pp.1203~1208 (2009)
- Lu SD, "Preoperative ratio of neutrophils to lymphocytes predicts postresection survival in selected patients with early or intermediate stage hepatocellular carcinoma", Medicine (Baltimore), 95, pp.e2722~ (2016)
- Liu Y, "Preoperative inflammation-based markers predict early and late recurrence of hepatocellular carcinoma after curative hepatectomy", Hepatobiliary Pancreat Dis Int, 15, pp.266~274 (2016)
- Goh BK, "Significance of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and prognostic nutrition index as preoperative predictors of early mortality after liver resection for huge(≥10 cm)hepatocellular carcinoma", J Surg Oncol, 113, pp.621~627 (2016)
- Okamura Y, "Preoperative neutrophil to lymphocyte ratio and prognostic nutritional index predict overall survival after hepatectomy for hepatocellular carcinoma", World J Surg, 39, pp.1501~1509 (2015)
- Okamura Y, "Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma", Br J Surg, 103, pp.891~898 (2016)
- Peng W, "Neutrophil to lymphocyte ratio changes predict small hepatocellular carcinoma survival", J Surg Res, 192, pp.402~408 (2014)
- Liao W, "Preoperative neutrophil-to-lymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection", Transl Oncol, 7, pp.248~255 (2014)
- Mano Y, "Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma : a retrospective analysis", Ann Surg, 258, pp.301~305 (2013)
- Wang Q, "The severity of liver fibrosis influences the prognostic value of inflammation-based scores in hepatitis B-associated hepatocellular carcinoma", Ann Surg Oncol, 22(Suppl 3), pp.S1125~S1132 (2015)
- Li C, "Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma", J Surg Res, 198, pp.73~79 (2015)
- Hernandez-Gea V, "Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma", Gastroenterology, 144, pp.512~527 (2013)
- Kuang DM, "Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma", J Hepatol, 54, pp.948~955 (2011)
- Zhang JP, "Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients", J Hepatol, 50, pp.980~989 (2009)
- Zhou SL, "Tumor-associated neutrophils recruit macrophages and T-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib", Gastroenterology, 150, pp.1646~1658 (2016)[DOI]
- Fu J, "Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients", Gastroenterology, 132, pp.2328~2339 (2007)